Elevai Labs, Common Stock Performance
| ELAB Stock | 1.99 0.11 5.24% |
The firm shows a Beta (market volatility) of -2.67, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Elevai Labs, are expected to decrease by larger amounts. On the other hand, during market turmoil, Elevai Labs, is expected to outperform it. At this point, Elevai Labs, Common has a negative expected return of -3.74%. Please make sure to confirm Elevai Labs,'s standard deviation, maximum drawdown, kurtosis, as well as the relationship between the total risk alpha and potential upside , to decide if Elevai Labs, Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Elevai Labs, Common has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.44 | Five Day Return (11.76) | Year To Date Return (99.44) | Ten Year Return (99.69) | All Time Return (99.69) |
Last Split Factor 1:200 | Last Split Date 2024-11-27 |
1 | Elevai Labs announces pricing of 8 million public offering | 09/23/2024 |
2 | SEC Form 424B3 filed by Elevai Labs Inc. - Quantisnow | 09/24/2024 |
3 | Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Inclu... | 10/03/2024 |
4 | Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin Activin-A Blocker, ... | 10/21/2024 |
5 | Dow Jumps 400 Points US Adds 12,000 Jobs In October | 11/01/2024 |
6 | Elevai Labs granted extension to meet Nasdaq listing standards | 11/13/2024 |
7 | Elevai Labs reports Q2 results | 11/15/2024 |
8 | Elevai Labs Inc.Announces Withdrawal of Offer to Exchange and P | 11/22/2024 |
9 | Elevai Labs Inc. Executes 1-for-200 Reverse Stock Split | 11/27/2024 |
| Begin Period Cash Flow | 1.2 M |
Elevai |
Elevai Labs, Relative Risk vs. Return Landscape
If you would invest 6,480 in Elevai Labs, Common on September 4, 2024 and sell it today you would lose (6,270) from holding Elevai Labs, Common or give up 96.76% of portfolio value over 90 days. Elevai Labs, Common is currently does not generate positive expected returns and assumes 15.5434% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Elevai, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Elevai Labs, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elevai Labs,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Elevai Labs, Common, and traders can use it to determine the average amount a Elevai Labs,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2406
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ELAB |
Estimated Market Risk
| 15.54 actual daily | 96 96% of assets are less volatile |
Expected Return
| -3.74 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Elevai Labs, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Elevai Labs, by adding Elevai Labs, to a well-diversified portfolio.
Elevai Labs, Fundamentals Growth
Elevai Stock prices reflect investors' perceptions of the future prospects and financial health of Elevai Labs,, and Elevai Labs, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Elevai Stock performance.
| Return On Equity | -3.51 | ||||
| Return On Asset | -0.89 | ||||
| Profit Margin | (1.92) % | ||||
| Operating Margin | (2.32) % | ||||
| Current Valuation | (23 K) | ||||
| Shares Outstanding | 3.07 M | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 2.99 X | ||||
| Revenue | 1.71 M | ||||
| EBITDA | (4.27 M) | ||||
| Net Income | (4.3 M) | ||||
| Total Debt | 210.49 K | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (4.56 M) | ||||
| Earnings Per Share | (88.92) X | ||||
| Market Capitalization | 7.41 M | ||||
| Total Asset | 5.19 M | ||||
| Retained Earnings | (7.02 M) | ||||
| Working Capital | 3.62 M | ||||
About Elevai Labs, Performance
By analyzing Elevai Labs,'s fundamental ratios, stakeholders can gain valuable insights into Elevai Labs,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Elevai Labs, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Elevai Labs, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 313.00 | 297.35 | |
| Return On Tangible Assets | (0.83) | (0.87) | |
| Return On Capital Employed | (0.94) | (0.90) | |
| Return On Assets | (0.83) | (0.87) | |
| Return On Equity | (1.12) | (1.07) |
Things to note about Elevai Labs, Common performance evaluation
Checking the ongoing alerts about Elevai Labs, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Elevai Labs, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Elevai Labs, Common generated a negative expected return over the last 90 days | |
| Elevai Labs, Common has high historical volatility and very poor performance | |
| Elevai Labs, Common may become a speculative penny stock | |
| The company reported the previous year's revenue of 1.71 M. Net Loss for the year was (4.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Elevai Labs, generates negative cash flow from operations | |
| Elevai Labs, Common has a frail financial position based on the latest SEC disclosures | |
| About 73.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Elevai Labs Inc. Executes 1-for-200 Reverse Stock Split |
- Analyzing Elevai Labs,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Elevai Labs,'s stock is overvalued or undervalued compared to its peers.
- Examining Elevai Labs,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Elevai Labs,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Elevai Labs,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Elevai Labs,'s stock. These opinions can provide insight into Elevai Labs,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Elevai Stock analysis
When running Elevai Labs,'s price analysis, check to measure Elevai Labs,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevai Labs, is operating at the current time. Most of Elevai Labs,'s value examination focuses on studying past and present price action to predict the probability of Elevai Labs,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevai Labs,'s price. Additionally, you may evaluate how the addition of Elevai Labs, to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |